Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

responsive web design (RWD)

Press release: InSite Event™ named one of the most innovative services of 2020

Press ReleaseContact: Jess Masciangelo, Business Development Directorjmasciangelo@impetusdigital.commeetwithimpetus.comINSITE EVENT™ NAMED ONE OF THE MOST INNOVATIVE SERVICES OF 2020Toronto, ON, December 10, 2020 — Impetus Digital’s new virtual event platform InSite Event™...

Impetus Digital

- PMLiVE

Advance Outcomes named of the most innovative strategies of 2020 by PM360

PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Lucid Group’s pioneering behaviour-change methodology, Advance OutcomesTM, as one of...

Lucid Group Communications Limited

- PMLiVE

J&J trims the size of its phase 3 COVID-19 vaccine trial

Company cuts size of participant population from 60,000 to 40,000

- PMLiVE

Canada joins UK in approving Pfizer/BioNTech COVID-19 vaccine

Health Canada will continue to monitor safety of jab

- PMLiVE

UK regulator warns of allergic reactions to Pfizer/BioNTech vaccine

New MHRA guidance comes after reports of allergic reactions to COVID-19 vaccine

- PMLiVE

ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

A round-up of some of the key data from the annual American Society of Hematology (ASH) meeting

- PMLiVE

FDA briefing document paves the way for Pfizer/BioNTech COVID-19 vaccine approval

Advisory Committee is set to meet today to discuss vaccine's safety and efficacy data

- PMLiVE

Digitising healthcare

by Peter Ruffley

- PMLiVE

Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib

Investigational drug beat Pfizer's Bosulif in phase 3 study

- PMLiVE

bluebird bio’s beta thalassaemia gene therapy Zynteglo scores promising long-term data

Results presented at annual American Society of Haematology (ASH) meeting

- PMLiVE

The Lancet confirms effectiveness of AZ/Oxford University’s COVID-19 vaccine

Final average efficacy analysis found to be 70.4%

Lucid Group Evolve and Simplify its Brand Architecture

The current pandemic has forced many industries to find new ways of working. Within medical communications (medcomms), this has involved pivoting quickly towards a digital-first approach in order to optimise...

Lucid Group Communications Limited

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links